Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc.

Bullboard Posts

Comment by topseekeron Jul 23, 2020 2:03pm

198 Views

Post# 31309194

RE:Interview

SoulTsunami wrote: https://www.youtube.com/watch?v=kp8lir6OCYk

Yes, thanks again. Progress continues and keeping in mind, Just 2 weeks of patients taking the meds will be sufficient to give critical data on the efficacy of taking Ifendropil. Incredibly short time frame. Concerning the shareholders sp outcome upon moving forward to Phase 3, will be more than dramatic.

Best wishes to All, good health,

Sincerely,

Topseeker

P.S. Certainly looking forward to more FYI with next week's ( Tues ) interview with AGN & Proactive NY. Topseeker

Bullboard Posts

Canada Nickel unveils second of seven resources planned by mid-2025